Kalaris Therapeutics, Inc.
Data quality: 83%
KLRS
Nasdaq
Manufacturing
Chemicals
$5.99
▼
$0.35
(-5.52%)
Mkt Cap: 137.34 M
Price
$5.99
Mkt Cap
137.34 M
Day Range
$5.83 — $6.64
52-Week Range
$2.14 — $11.88
Volume
60,393
Open $6.40
50D / 200D Avg
$8.65
30.76% below
50D / 200D Avg
$6.00
0.20% below
Quick Summary
Key Takeaways
Negative free cash flow of -38.57 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-91.47%
Below sector avg (-51.02%)
ROIC-45.49%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio12.89
Interest Coverage-31.98
Valuation
PE (TTM)
-3.16
Below sector avg (-1.98)
P/B Ratio3.28
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (44 peers)
Peer Comparison
vs Manufacturing sector median (44 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -3.2 | -2.0 |
| P/B | 3.3 | 5.1 |
| ROE % | -91.5 | -51.0 |
| Net Margin % | — | -150.2 |
| Rev Growth 5Y % | — | 9.3 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -43.44 M |
| ROE | -91.47% | ROA | -49.92% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -38.57 M |
| ROIC | -45.49% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 12.89 |
| Interest Coverage | -31.98 | Asset Turnover | N/A |
| Working Capital | 72.12 M | Tangible Book Value | 41.87 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -3.16 | Forward P/E | N/A |
| P/B Ratio | 3.28 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -28.08% | ||
| Market Cap | 137.34 M | Enterprise Value | 94.95 M |
| Per Share | |||
| EPS (Diluted TTM) | -2.85 | Revenue / Share | N/A |
| FCF / Share | -1.68 | OCF / Share | -1.67 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 88.79% |
| SBC-Adj. FCF | -45.12 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -43.44 M | -58.77 M | -190.42 M | -168.71 M | -171.96 M |
| EPS (Diluted) | -2.85 | -11.73 | -1.83 | -2.20 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -46.15 M | -65.44 M | -199.90 M | -171.20 M | -169.82 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 30.75 M | 12.34 M | 133.07 M | 118.87 M | 120.74 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | 398,000.0 | 398,000.0 | 723,000.0 | 189,000.0 |
| Interest Expense | 1.44 M | — | — | — | — |
| Income Tax | 0.0 | 0.0 | -126,000.0 | -265,000.0 | 1.01 M |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 121.74 M | 118.55 M | 190.80 M | 277.08 M | 286.59 M |
| Total Liabilities | 42.92 M | 5.24 M | 45.02 M | 52.56 M | 61.33 M |
| Shareholders' Equity | 78.81 M | 113.31 M | 145.78 M | 224.52 M | 225.27 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 98.05 M | 118.29 M | 90.12 M | 106.09 M | 201.66 M |
| Current Assets | 118.81 M | 118.55 M | 187.64 M | 243.05 M | 253.35 M |
| Current Liabilities | 9.71 M | 5.24 M | 28.37 M | 24.34 M | 37.85 M |
{"event":"ticker_viewed","properties":{"ticker":"KLRS","listing_kind":"stock","pathname":"/stocks/klrs","exchange":"Nasdaq","country":"US"}}